- Zacks Small Cap Research•4 months ago
Q4 revenue was $276k (vs. $375k estimate), all of which relates to product sales. As a reminder, as a result of the conclusion of services related to a two-year contract, SBOT has not booked any contract services-related revenue since fiscal Q1 2016. Gross margin was a relatively very healthy 26% in Q4, driven by product margin of 57% - which looks to be an all-time high. We continue to look for both greater stabilization and growth of gross margin with higher KLH production volumes as SBOT supports larger clinical trials and brings on additional contracts and supply agreements. Operating expenses were $1.4M, up about 29% and 17% from the year-earlier and quarter-earlier periods, respectively, but about 6% lower than what we were anticipating. Stellar recently brought on additional professional personnel in anticipation of increased demand for KLH and eventual production scale-up. While this will have the effect of incrementally pushing up OpEx, this should be at least partially offset by expected near-term revenue growth and expanding gross margins.
- Insider Monkey•10 months ago
Stocks are trading in the green on Thursday as markets continue to steadily recover from the Brexit-triggered wild swings. However, investors remain selective as the future of the global economy is still dotted with uncertainties after UK’s exit from the European Union. Meanwhile, some stocks are worth watching closely today, including TESARO Inc (NASDAQ:TSRO), Stellar […]
- Marketwired•last year
Stellar Biotechnologies, Inc. , the leader in sustainable manufacture of Keyhole Limpet Hemocyanin, today announced that the Company's voluntary delisting from the TSX Venture Exchange will be effective ...
Requested symbol wasn't found
TSXV - TSXV Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|